Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$56.78 USD
-0.18 (-0.32%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.74 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$56.78 USD
-0.18 (-0.32%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $56.74 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Zacks News
After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
by Zacks Equity Research
Ultragenyx (RARE) reports preliminary full-year 2023 revenues, along with business updates, and shares 2024 revenue guidance.
Ultragenyx (RARE) Posts Update From AS Study of GTX-102
by Zacks Equity Research
Ultragenyx (RARE) completes enrollment in the phase I/II study of GTX-102 for the treatment of pediatric patients with AS. Top-line data from the study is expected in the first half of 2024.
Does Ultragenyx (RARE) Have the Potential to Rally 87.43% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Ultragenyx (RARE) points to an 87.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports weaker-than-expected third-quarter 2023 results, missing earnings and sales estimates. Management reiterates the 2023 financial outlook.
Ultragenyx (RARE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Will Kymera Therapeutics, Inc. (KYMR) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Ultragenyx (RARE) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Horizon Therapeutics (HZNP) Up 10.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Ultragenyx (RARE) reports mixed second-quarter 2023 results, maintaining its 2023 financial guidance. The company's pipeline progress is also on track.
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.64% and 2.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Reports Next Week: What You Should Expect
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Doses First Patients in Bone Disease Studies
by Zacks Equity Research
Ultragenyx (RARE) announces dosing the first patients in its phase III studies evaluating setrusumab (UX143) in young adult and pediatric patients with osteogenesis imperfecta.
Why Is Exact Sciences (EXAS) Up 11.5% Since Last Earnings Report?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report?
by Zacks Equity Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Posts Data From Osteogenesis Imperfecta Study
by Zacks Equity Research
Ultragenyx (RARE), along with partner Mereo BioPharma, announces encouraging data on mid-stage study evaluating setrusumab for patients with osteogenesis imperfecta.
Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
by Zacks Equity Research
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -18.27% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (ALLO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of -7.94% and 35%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?